FDG Oncology

Positron emission tomography (PET) has demonstrated varying levels of accuracy, sensitivity, specificity, and impact on patient management across different cancer types.

Here is a summary of the available data regarding PET's accuracy, sensitivity, specificity, and impact on patient management for several cancer types:

Non-Small Cell Lung Cancer (NSCLC):

Accuracy: PET has shown high accuracy in the staging and restaging of NSCLC, with reported sensitivity ranging from 80% to 96% and specificity ranging from 73% to 90%.

Impact on Patient Management: PET has a significant impact on patient management by providing information for treatment planning, guiding the selection of appropriate therapy, and assessing response to treatment.

Small Cell Lung Cancer (SCLC):

Accuracy: PET has demonstrated high accuracy in the initial staging of SCLC, with reported sensitivity ranging from 78% to 96% and specificity ranging from 83% to 95%.

Impact on Patient Management: PET plays a crucial role in staging and identifying metastatic disease, which helps guide treatment decisions and may prevent unnecessary surgery.

read more

Lymphoma:

Accuracy: PET has shown high accuracy in the initial staging, restaging, and response assessment of both Hodgkin’s lymphoma and non-Hodgkin lymphoma. Reported sensitivity ranges from 80% to 100%, and specificity ranges from 64% to 100% depending on the specific lymphoma subtype.

Impact on Patient Management: PET has a significant impact on treatment decisions, including disease staging, therapy selection, response evaluation, and monitoring of residual disease.

read more

Breast Cancer:

Accuracy: PET has demonstrated variable accuracy in breast cancer imaging, with reported sensitivity ranging from 60% to 96% and specificity ranging from 56% to 95%. Its accuracy is influenced by factors such as tumor size, histological type, and hormonal receptor status.

Impact on Patient Management: PET has a modest impact on patient management in breast cancer, primarily in cases of suspected distant metastases or in the evaluation of tumor recurrence.

read more

Prostate Cancer:

Accuracy: PET, specifically using prostate-specific membrane antigen (PSMA) tracers, has shown high accuracy in the detection of recurrent prostate cancer, with reported sensitivity ranging from 75% to 97% and specificity ranging from 79% to 100%.

Impact on Patient Management: PSMA PET has a substantial impact on patient management, influencing treatment decisions, guiding targeted therapies, and identifying sites for local or metastatic disease.

read more

Colorectal Cancer:

Accuracy: PET has demonstrated variable accuracy in colorectal cancer imaging, with reported sensitivity ranging from 66% to 97% and specificity ranging from 51% to 98%. Its accuracy is influenced by factors such as tumor size, location, and presence of distant metastases.

Impact on Patient Management: PET can impact patient management by identifying distant metastases, guiding treatment decisions, evaluating treatment response, and detecting tumor recurrence.

read more

Gynecological Cancers:

Accuracy: PET has shown varying accuracy across different gynecological cancers, with reported sensitivity ranging from 47% to 100% and specificity ranging from 72% to 97%. Its accuracy is influenced by factors such as tumor type, size, and location.

Impact on Patient Management: PET plays a role in staging, restaging, and treatment response evaluation in gynecological cancers, assisting in treatment planning and decision-making.

read more

Head and Neck Cancers:

Accuracy: PET has demonstrated good accuracy in head and neck cancer imaging, with reported sensitivity ranging from 70% to 100% and specificity ranging from 80% to 100%. Its accuracy is influenced by factors such as tumor location, size, and histological type.

Impact on Patient Management: PET is valuable in the initial staging, restaging, and detection of recurrent disease, guiding treatment decisions, and evaluating treatment response.

read more

Multiple Myeloma:

Accuracy: PET has shown variable accuracy in multiple myeloma imaging, with reported sensitivity ranging from 57% to 98% and specificity ranging from 50% to 100%. Its accuracy is influenced by factors such as disease activity, tumor burden, and presence of extramedullary disease.

Impact on Patient Management: PET can influence patient management by providing information on disease extent, identifying extramedullary lesions, and monitoring treatment response.

read more

Melanoma:

Accuracy: PET has demonstrated good accuracy in melanoma imaging, with reported sensitivity ranging from 67% to 100% and specificity ranging from 52% to 100%. Its accuracy is influenced by factors such as tumor thickness, ulceration, and lymph node involvement.

Impact on Patient Management: PET plays a role in the staging and restaging of melanoma, assisting in treatment planning, evaluating lymph node involvement, and detecting distant metastases.

It’s important to note that the reported sensitivity, specificity, and impact on patient management can vary depending on the specific study, patient population, and imaging protocols used. These values are approximate ranges based on available literature and may not be universally applicable. It is always recommended to consult with healthcare professionals for individualized assessment and interpretation of PET imaging results.